In one clinical trial, SAA was a highly significant predictor of CD severity, and treatment with filgotinib, a selective JAK1/STAT inhibitor, improved CD symptoms while simultaneously reducing circulating SAA levels (223). Here, SAA2 is linked to Cowden disease.